HFE-associated hereditary hemochromatosis.

Area of Science:

• Genetics
• Gastroenterology
• Internal Medicine

Background:

• Hereditary hemochromatosis is the most common inherited iron overload disorder, particularly in Northern European populations.
• The p.C282Y mutation in the HFE gene is a primary cause, leading to inappropriately low hepcidin secretion and subsequent iron accumulation.
• Clinical manifestations range from liver disease (cirrhosis, cancer) to diabetes and cardiomyopathy.

Purpose of the Study:

• To review the pathophysiology, clinical features, diagnosis, and management of HFE-associated hereditary hemochromatosis.
• To discuss the role of genetic testing in diagnosis and family screening.

Main Methods:

• Review of existing literature on HFE-associated hereditary hemochromatosis.
• Discussion of diagnostic biochemical and molecular genetic tests.
• Evaluation of treatment strategies, primarily phlebotomy.

Main Results:

• The p.C282Y HFE mutation is prevalent and linked to iron overload due to impaired hepcidin regulation.
• Biochemical markers include elevated transferrin saturation and ferritin; clinical signs involve multiple organ systems.
• Phlebotomy is an effective treatment if initiated before cirrhosis develops.

Conclusions:

• Most patients are diagnosed before severe clinical manifestations appear, with molecular genetic tests aiding diagnosis.
• Population-wide genetic screening is not advised due to low yield in asymptomatic carriers.
• HFE gene testing is valuable for screening first-degree relatives of affected individuals.